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INTRODUCTION 
Systemic adjuvant therapies following surgical removal of the
primary tumour are advocated in patients with early breast cancer
with the aim of eliminating or reducing the incidence of distant
metastases, ultimately prolonging disease-free survival (DFS) and
overall survival (OS). The presence of endogenous oestradiol
plays a significant role in the progression of disease and its impact
is largely dependent on the hormone receptor status of the tumour.
Approximately 60% of pre-/perimenopausal patients with primary
breast cancer have oestrogen-receptor (ER)-positive tumours
(Pujol et al, 1998; Aebi et al, 2000; Kroman et al, 2000). Thus,
removal of the source of endogenous oestrogen in premenopausal
patients is likely to prevent growth of tumours that are sensitive to
circulating oestrogens. 
The value of adjuvant ovarian ablation has long been recog-
nized as a valuable treatment option for premenopausal women
with early breast cancer. This was confirmed in 1996 by the Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG, 1996). In
reviewing data from adjuvant trials, they found that in 2102
women under 50 years-of-age with node-negative or node-positive
early breast cancer, ablation of functioning ovaries by surgical
oophorectomy or radiotherapy significantly improved 15-year
disease-free and overall survival compared with controls. In direct
(Scottish Cancer Trials Breast Group and ICRF Breast Unit, 1993;
Ejlertsen et al, 1999) and indirect (EBCTCG, 1992) comparisons,
ovarian ablation has been shown to have comparable efficacy to
chemotherapy. Despite the efficacy of ovarian ablation by surgery
or irradiation in prolonging survival, they generally induce a
permanent menopause with associated long-term effects, such as
loss of bone mineral density (BMD) and increased risk for cardio-
vascular problems (Goodwin et al, 1999; Pfeilschifter and Diel,
2000). Growing evidence indicates that there may be additional
benefits offered by medical endocrine therapies which induce a
reversible state of ovarian suppression. 
Over the past decade, the luteinizing hormone releasing
hormone (LHRH) analogue goserelin (Zoladex™) alone (Blamey
et al, 1992; 1993), or with tamoxifen (Jonat et al, 1995), has
proven effective for the treatment of advanced (metastatic or
locally advanced) breast cancer in pre-/perimenopausal women
resulting in objective response rates similar to oophorectomy
(Boccardo et al, 1994; Taylor et al, 1998). This success of
goserelin in treating metastatic disease, and more recently the
growing evidence from ongoing international trials of goserelin in
early disease, indicate that goserelin may provide a valuable alter-
native to chemotherapy for premenopausal women with hormone
receptor-positive early breast cancer. 
MODE OF ACTION OF GOSERELIN 
LHRH analogues, such as goserelin, reduce circulating concentra-
tions of oestrogen in premenopausal women via an inhibitory
effect on the hypothalamic–pituitary–ovarian axis. At the cellular
level, LHRH analogues bind to LHRH receptors on pituitary gland
cells, an action which causes an initial surge in the secretion of
luteinizing hormone (LH). Once bound to ligand, these LHRH
receptors form clusters, which are then sequestered within the cell,
thereby reducing the number of unoccupied LHRH receptors.
These unoccupied receptors are maintained at low levels by the
presence of the LHRH analogue, ultimately resulting in reduced
LH secretion. In turn, the reduced plasma LH causes a decrease in
circulatory oestradiol (the main source of oestrogen in
premenopausal women) to levels comparable to the post-
menopausal state within 21 days, which are maintained with
continued administration of LHRH analogues (Furr, 1989). 
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Summary Current standard adjuvant therapies for premenopausal women with early breast cancer include ovarian ablation by surgery or
irradiation, chemotherapy and tamoxifen. The value of ovarian ablation in prolonging the survival of premenopausal patients with early breast
cancer was clearly established by the analyses performed by the Early Breast Cancer Trialists’ Collaborative Group in 1996. More recently,
the value of ovarian suppression using the luteinizing hormone releasing hormone analogue goserelin as adjuvant therapy in 
pre-/perimenopausal women with early breast cancer has been confirmed in a series of studies involving over 8000 patients. The results from
these studies provide evidence that goserelin, alone or in combination with tamoxifen, is at least as effective as cytotoxic chemotherapy in
patients with hormone receptor-positive tumours and is effective when used after adjuvant chemotherapy. The use of goserelin in the
management of early breast cancer presents an option which can avoid the side-effects experienced with cytotoxic chemotherapy and may
offer unique benefits to premenopausal patients. The consolidation of these emerging results should help in defining the optimal role for
goserelin in pre-/perimenopausal patients with early breast cancer. © 2001 Cancer Research Campaign. 
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PRE-/PERIMENOPAUSAL PATIENTS 
Current adjuvant therapies for the pre-/perimenopausal patient
with early breast cancer include: ovarian ablation or medical
ovarian suppression with or without tamoxifen; tamoxifen alone;
or postoperative chemotherapy with or without tamoxifen. 
The choice of adjuvant therapy for pre- and perimenopausal
women with early breast cancer is heavily influenced by prog-
nostic and predictive factors. Such factors include: axillary lymph
node status, tumour size, histological or nuclear grade of the
tumour, menopausal status and hormone-receptor status. The
hormone-receptor status of the tumour – both ER and progesterone
receptor (PgR) – is highly predictive of the response to endocrine
therapies (EBCTCG, 1998). In particular, patients with tumours
expressing ER and PgR tend to show a greater response rate and
prolonged DFS and overall survival when treated with endocrine
therapies (Clark, 1999; EBCTCG, 1998). Consequently, there is a
strong case for trying to identify those patients who are most likely
to respond favourably to adjuvant endocrine treatment. Ovarian
ablation achieved by LHRH analogue therapy may be an impor-
tant treatment option in these patients, offering a targeted, poten-
tially reversible ovarian suppression that may avoid the long-term
effects associated with premature menopause. 
UPDATE OF GOSERELIN IN CLINICAL TRIALS 
A number of ongoing trials involving pre-/perimenopausal women
with early breast cancer are now reporting on the efficacy and
tolerability of goserelin, either alone or in combination with
tamoxifen, and as an alternative or in addition to standard
chemotherapy regimens (Figure 1). This programme of trials was
designed to investigate the use of goserelin in different settings in
order to define more clearly the future role of goserelin in early
breast cancer. 
Goserelin monotherapy 
‘Zoladex’ Early Breast Cancer Research Association
(ZEBRA) trial 
The ZEBRA trial represents the first direct comparison of adjuvant
goserelin monotherapy with chemotherapy in pre-/perimenopausal
patients aged 50 years or less with node-positive early breast
cancer. This large (n = 1640), randomized, multicentre (102
centres) trial assessed the effect of these treatments on DFS, OS
and the side-effect profile associated with each treatment. The
ZEBRA trial protocol also included sub-studies to assess quality
of life (QoL) and BMD. 
The ZEBRA study reported that goserelin (3.6 mg every 
28 days for 2 years) was equivalent to cyclophosphamide/
methotrexate/5-fluorouracil (CMF, 6 × 28-day cycles) for DFS in
ER-positive patients after a median follow-up of 6 years (HR =
1.01, 95% CI = 0.84–1.20) (Kaufmann, 2001). The patients with
ER-positive tumours accounted for approximately 74% of the
study population. However, for ER-negative patients (approxi-
mately 19% of the study population), there was a significant
advantage in favour of CMF for DFS (HR = 1.76, 95% CI =
1.27–2.44). The onset of amenorrhoea occurred more rapidly with
goserelin treatment than with CMF, with over 95% of patients
receiving goserelin achieving amenorrhoea by 6 months,
compared with approximately 60% of patients in the CMF group.
Furthermore, amenorrhoea was found to be reversible in the
majority of patients receiving goserelin but permanent with CMF:
only 23% of goserelin patients remained amenorrhoeic at 3 years
compared with 77% in the CMF group (Jonat, 2000). 
In terms of tolerability to therapy, typical side-effects of
chemotherapy (e.g. alopecia, nausea and vomiting, and infection)
were substantially higher in patients receiving CMF during the 6-
month CMF treatment period. Menopausal symptoms (e.g. vaginal
dryness and hot flushes) were initially lower in the CMF group
compared with the goserelin group. However, these endocrine-
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Figure 1 Clinical trials designs for studies involved in the evaluation of goserelin as adjuvant treatment in early breast cancer in pre-/perimenopausal patients related side-effects remained virtually unchanged in the CMF
group during follow-up, whereas 1 year after the cessation of
goserelin the incidence of these effects decreased to below that in
the CMF group (Jonat, 2000). 
In total, 514 patients receiving goserelin and 496 patients
receiving CMF in 86 centres were included in the QoL sub-study.
The improvement from baseline in overall QoL score was signifi-
cantly (P < 0.0001) greater in the goserelin-treated group
compared with the CMF-treated group during the first 3–6 months.
However, at 1, 2 and 3 years there were no significant differences
in overall QoL scores between the two treatment groups (de Haes,
2001). 
In the BMD sub-study, eight centres contributed data from 96
selected patients. Losses in BMD were observed for both treat-
ment groups during the first 2 years of the study, with the losses
being greater in the goserelin group. However, at 3 years (1 year
after cessation of goserelin therapy), partial recovery of BMD was
seen in the goserelin group, whereas losses persisted in the CMF
group overall throughout follow-up. As a result, no significant
differences in BMD were observed between the two treatment
groups at the 3-year assessment. In addition, the observed changes
in BMD levels appeared to be related to menstrual status in both
treatment groups (Fogelman, 2001). 
Goserelin plus tamoxifen 
The Austrian Breast Cancer Study Group (ABCSG) ACO5
trial 
The ABCSG trial was designed to compare ovarian suppression
with goserelin plus tamoxifen versus CMF in premenopausal
patients with ER-positive/PgR-positive, node-positive/node-nega-
tive breast cancer (Jakesz et al, 2001). At a median follow-up of 50
months, results from 1088 evaluable patients showed a signifi-
cantly improved recurrence-free survival for goserelin and tamox-
ifen combination therapy compared with CMF therapy (P < 0.02). 
Italian Breast Cancer Adjuvant Study Group (GROCTA 02)
trial 
The GROCTA 02 trial was a randomized trial designed to compare
the efficacy of chemotherapy (CMF, n = 120) with that of tamox-
ifen plus ovarian suppression (oophorectomy n = 6, ovarian irradi-
ation n = 31, goserelin n = 87) in 244 pre-/perimenopausal patients
with node-positive/node-negative, ER-positive breast cancer
(Boccardo et al, 2000; 2001). Results at a median follow-up of 89
months revealed that tamoxifen plus ovarian suppression achieved
comparable results in terms of DFS and OS to those of CMF,
regardless of nodal status. Furthermore, there was no difference in
clinical outcome of patients treated with oophorectomy or ovarian
irradiation compared with those treated with goserelin. 
Goserelin in addition to standard therapy 
Zoladex in Premenopausal Patients (ZIPP) trial 
The ZIPP trial was designed to investigate the effect of adding
goserelin to standard therapy (surgery ± radiotherapy ± cytotoxic
chemotherapy ± tamoxifen) in premenopausal patients with early
breast cancer, regardless of nodal or tumour ER status. Patients
were randomized to receive goserelin, tamoxifen, goserelin plus
tamoxifen or no further treatment. Of the 2710 patients random-
ized, 2032 were of known tumour ER status and of these 68% were
ER-positive. Patients who received goserelin in addition to
standard therapy showed a significant improvement in recurrence-
free survival (RR = 0.80, 95% CI = 0.70–0.92, P < 0.001) and
overall survival (RR = 0.82, 95% CI = 0.67–0.99, P = 0.04)
compared with those who did not receive goserelin (Baum et al,
2001). 
Goserelin alone or combined with tamoxifen following
cytotoxic chemotherapy 
Eastern Cooperative Oncology Group (ECOG)/South
Western Oncology Group (SWOG)/Cancer and Leukemia
Group B (CALGB) – INT-0101 trial 
This trial was instigated to assess the use of goserelin with or
without tamoxifen following chemotherapy. In 1504 eligible
premenopausal patients with node-positive, hormone receptor-
positive breast cancer, patients receiving six cycles of cyclophos-
phamide/adriamycin/5-fluorouracil (CAF) were compared with
patients receiving CAF followed by goserelin (Z) either alone
(CAFZ) or with tamoxifen (CAFZT) (Davidson et al, 1999). There
was a significant (P < 0.01) improvement in 5-year DFS for
CAFZT-treated patients (77%) compared with patients treated
with CAFZ (70%), with a trend towards improved 5-year DFS for
CAFZ versus CAF (67%). 
Goserelin alone or in combination with cytotoxic
chemotherapy 
International Breast Cancer Study Group (IBCSG) VIII trial 
In the IBCSG VIII trial, 1060 premenopausal patients with node-
negative, hormone receptor-positive/negative early breast cancer
were initially randomized to CMF followed by goserelin, CMF
alone, goserelin alone or no treatment. The no-treatment arm was
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Table 1 Summary of key results to date from the goserelin adjuvant trials
programme involving pre-/perimenopausal patients with early breast cancer 
Trial Key results 
ZEBRA Goserelin demonstrates equivalent 
efficacy to CMF in patients with 
ER-positive tumours but without the
distressing side-effects of cytotoxic
chemotherapy 
ZEBRA Amenorrhoea and associated 
side-effects are reversible with
goserelin in the majority of patients but
appear to be permanent with CMF 
GROCTA 02 and ABCSG AC05 Goserelin combined with tamoxifen is at 
least as effective as CMF in patients
with hormone receptor-positive
tumours 
ZIPP Addition of goserelin to standard therapy 
(± radiotherapy ± chemotherapy ±
tamoxifen) is beneficial 
INT-0101 Addition of goserelin, alone or in 
combination with tamoxifen, to CAF
therapy is beneficial in patients with
hormone receptor-positive tumours 
IBCSG VIII Adjuvant therapy in node-negative, 
premenopausal patients improves
outcome compared with no adjuvant
therapy subsequently dropped because evidence from other trials showed
that adjuvant treatment improved outcome in this patient popula-
tion. An analysis of the effect of adjuvant treatment compared with
no adjuvant treatment in this trial has confirmed that adjuvant
treatment improves outcome in premenopausal patients with node-
negative early breast cancer (Castiglione-Gertsch et al, 2000).
Further results from this trial are awaited. 
TRIALS SUMMARY 
A summary of the key findings from trials involving goserelin for
the treatment of pre-/perimenopausal patients with early breast
cancer is shown in Table 1. The ZEBRA trial is the first report of a
direct comparison of LHRH analogue monotherapy with cytotoxic
chemotherapy following initial removal of the primary tumour by
surgery (± radiotherapy) in pre-/perimenopausal patients with
early breast cancer. The results from this trial show that, in this
patient population, goserelin demonstrates equivalent efficacy to
CMF in patients with ER-positive tumours. The randomized trials
discussed in this review support the use of goserelin alone or
combined with tamoxifen and/or cytotoxic chemotherapy or inte-
grated into treatment strategies following standard therapy to
provide a beneficial effect in premenopausal patients with
hormone receptor-positive early breast cancer. 
CONCLUSIONS 
Ovarian suppression undoubtedly provides a valuable treatment
option in premenopausal patients with hormone receptor-positive
tumours. Goserelin provides an alternative to cytotoxic
chemotherapy without the associated distressing side-effects.
Consequently, the addition of goserelin to the adjuvant treatment
armamentarium further extends the choice of treatments available
to premenopausal women with hormone receptor-positive breast
cancer. It provides the opportunity of a temporary, rather than
permanent, ovarian ablation, without loss of efficacy when
compared with CMF treatment. Moreover, goserelin offers a
means of avoiding cytotoxic chemotherapy which may be a
requirement for some patients, and also a treatment which, in some
patients, may be combined with tamoxifen and/or cytotoxic
chemotherapy, with beneficial results. 
The benefits of a temporary ablation in premenopausal patients
should not be underestimated; not only does it avoid the long-term
consequences on, for example, the cardiovascular system and
BMD, it also offers this patient group a choice which avoids the
need for cytotoxic chemotherapy. In addition, hormone receptor
status clearly plays an important role in treatment outcome with
endocrine therapies and these studies confirm the need for routine
diagnosis of hormone receptor status in the management of early
breast cancer, to identify patients most likely to benefit from
endocrine therapies. 
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